ArticlePloS one2025
Mitochondrial dysfunction-related metabolite methylmalonic acid is associated with decreased cognitive performance.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMethylmalonic acid (MMA), a mitochondrial metabolite derived from propionate metabolism, has been implicated in fatal neurodegeneration in children with congenital methylmalonic acidemia. However, its clinical relevance in chronic cognitive decline remains poorly understood. This study aims to investigate the association between MMA levels, its metabolic coenzyme vitamin B12, and cognitive impairment in an elderly population. PATIENTS AND
methodsThe cohort comprised 2,762 participants aged 60 and older, who underwent assessments using the Digit Symbol Substitution Test (DSST), Animal Fluency test (AFT), Consortium to Establish a Registry for Alzheimer's disease (CERAD) Immediate Recall (CERAD-IR), CERAD Delayed Recall (CERAD-DR), with low cognitive performance defined as the bottom quartile. Generalized linear regression models were applied to explore potential associations. Additionally, differentially expressed genes (DEGs) in MMA-related propionate metabolic process were identified from the RNA expression profiles in frontal cortex from 56 Alzheimer's disease and 44 non-dementia controls.
resultsAmong the 2,762 participants, with a mean age of 69.2 years and 53.8% female, elevated MMA levels were significantly associated with an increased likelihood of low cognitive performance across multiple tests: DSST (OR = 1.95; 95% CI: 1.41-2.73), AFT (OR = 1.51; 95% CI: 1.01-2.25), CERAD-IR (OR = 1.58; 95% CI: 1.19-2.09), and CERAD-DR (OR = 1.56; 95% CI: 1.12-2.18). High serum vitamin B12 levels were associated with an increased likelihood of impaired CERAD-IR scores, although dietary B12 supplementation did not correlate with cognitive performance. Stratified analyses revealed a stronger relationship between MMA and cognitive decline in males, individuals over 75 years, and those with elevated serum and dietary vitamin B12 levels. DEG analysis identified genes related to MMA synthesis and mitochondrial function in cognitively impaired individuals, with significant enrichment in mitochondrial propionate metabolism pathways.
conclusionThe findings indicate that elevated MMA levels are linked to cognitive decline in older adults, potentially through mitochondrial dysfunction. These results underscore the clinical importance of MMA in the context of chronic cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.